ADC Therapeutics SA
Combination therapy with an anti-axl antibody-drug conjugate

Last updated:

Abstract:

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Status:
Grant
Type:

Utility

Filling date:

21 Nov 2018

Issue date:

28 Jan 2020